Get the Stockscreener App
41.18
1.19%
-0.61
Xenon Pharmaceuticals Inc stock is traded at $41.18, with a volume of 1.15M.
It is down -1.19% in the last 24 hours and down -8.26% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$41.79
Open:
$41.62
24h Volume:
1.15M
Relative Volume:
1.44
Market Cap:
$3.18B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-15.03
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
-6.41%
1M Performance:
-8.26%
6M Performance:
+24.15%
1Y Performance:
+1.41%
1-Day Range:
$40.41
$42.27
1-Week Range:
$40.41
$46.36
52-Week Range:
$26.74
$46.60
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
41.17 | 3.23B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.85 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.46 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.59 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.74 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Why Xenon Pharmaceuticals Inc. stock remains undervalued2026 world cup usa national team third place match playmakers high defensive line expert forecast preview - Улправда
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears - ts2.tech
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighTime to Buy? - MarketBeat
Xenon to Showcase Neuroscience Pipeline at J.P. Morgan Healthcare Conference - TipRanks
Cantor Fitzgerald raises Xenon Pharmaceuticals stock price target to $55 By Investing.com - Investing.com UK
Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
(XENE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy? - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% HigherHere's Why - MarketBeat
Analysts Conflicted on These Healthcare Names: Lifecore Biomedical (LFCR) and Xenon (XENE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options - Nasdaq
Xenon announces new data on 48-month azetukalner OLE study data - MSN
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com Canada
Biohaven Misses The Mark In Depression Trial, Stock Falls - Sahm
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Why (XENE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Can Xenon Pharmaceuticals Inc. stock deliver surprise earnings beatMarket Performance Summary & Stepwise Swing Trade Plans - bolumsonucanavari.com
Pullback Watch: How rising interest rates impact Xenon Pharmaceuticals Inc. stockMarket Sentiment Report & Growth Focused Stock Pick Reports - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Returns Recap: Why Xenon Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Capital Efficient Trading Techniques - Улправда
Will Xenon Pharmaceuticals Inc. stock outperform tech sector in 20252025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Can Xenon Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Precise Entry and Exit Recommendations - Улправда
Is Xenon Pharmaceuticals Inc. stock attractive for passive investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
How rising interest rates impact Xenon Pharmaceuticals Inc. stockForecast Cut & High Conviction Buy Zone Alerts - Улправда
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch PreparationSlideshow (NASDAQ:XENE) 2025-12-12 - Seeking Alpha
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo Maintains Xenon Pharmaceuticals (XENE) Overweight Recommendation - Nasdaq
XENE Stock Update: Wells Fargo Raises Price Target to $48 | XENE - GuruFocus
Russell Investments Group Ltd. Decreases Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline - MSN
Transcript : Xenon Pharmaceuticals Inc.Special Call - marketscreener.com
Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 14,375 Shares of Stock - MarketBeat
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares - Investing.com
Xenon Pharmaceuticals President & CEO Ian Mortimer Sells Shares - TradingView — Track All Markets
Xenon Pharmaceuticals unveils promising long-term epilepsy treatment data - MSN
CEO Mortimer Files To Sell 10,830 Of Xenon Pharmaceuticals Inc [XENE] - TradingView — Track All Markets
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year High – Here’s What Happened - Defense World
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance
Xenon Pharmaceuticals issues equity inducement grants to new employees - MSN
New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xenon Pharmaceuticals Inc Stock (XENE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Jan 02 '26 |
Sale |
44.43 |
40,000 |
1,777,093 |
6,000 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):